We also tested a different transgenic model of MYC-driven luminal B breast cancer (WAP-MYC)61 and also found that triple combination therapy (CpG/aOX40 + anti-PD-L1) resulted in improved responses and significantly improved survival (Fig. 4l). This evidence concerns the gene MYC and breast cancer.